Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have earned an average rating of “Hold” from the twenty-eight brokerages that are currently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a sell rating, thirteen have issued a hold rating and nine have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $32.2963.

A number of research analysts have commented on the company. Citigroup boosted their price objective on Sarepta Therapeutics from $9.00 to $13.00 and gave the stock a “sell” rating in a research note on Thursday. Weiss Ratings reiterated a “sell (d)” rating on shares of Sarepta Therapeutics in a report on Monday, December 29th. HC Wainwright reissued a “sell” rating on shares of Sarepta Therapeutics in a research report on Monday, March 2nd. Wall Street Zen upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Mizuho increased their price objective on shares of Sarepta Therapeutics from $26.00 to $31.00 and gave the company an “outperform” rating in a research report on Thursday, March 12th.

Key Headlines Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Early Phase 1/2 siRNA results point to target knockdown, muscle exposure and tolerability for SRP‑1001 and SRP‑1003 — the primary catalyst behind the rally. Business Wire: Sarepta Announces First Clinical Data
• Positive Sentiment: Multiple outlets and market commentators highlight the clinical readouts as a potential turning point; coverage helped drive heavy volume and momentum into the stock. Yahoo Finance: SRPT Stock Surges
• Positive Sentiment: Some sell‑side moves reflected renewed conviction — Morgan Stanley is reported to have raised its price target (reported widely alongside the trial coverage), which helped fuel the rally. InsiderMonkey: Morgan Stanley PT Hike
• Positive Sentiment: Unusually heavy options and call buying accompanied the move, indicating speculative bullish positioning and short‑term leverage from traders.
• Neutral Sentiment: Several valuation and note‑style writeups are trying to size the opportunity vs. risk — analysts and outlets caution that early Phase 1/2 data need confirmation and that valuation debate will drive near‑term swings. Yahoo/Zacks coverage: Is Further Upside Left?
• Negative Sentiment: Some firms remain skeptical — Citigroup raised a price target modestly but kept a sell rating (cites downside from current levels), and Needham reaffirmed an underperform stance, keeping sell‑side views polarized. Benzinga: Analyst Ratings
• Negative Sentiment: Independent analysts and commentators warn the data are early — some outlets argue it’s too soon to extrapolate durable clinical or commercial success from small Phase 1/2 cohorts. Seeking Alpha: Too Early to Get Excited
• Negative Sentiment: Underlying fundamentals and priorquarter results (recent EPS miss and revenue decline vs. year‑ago) remain a drag on sentiment; this increases the chance of volatility if follow‑up data or guidance disappoints.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Stephen Mayo sold 7,239 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total value of $123,207.78. Following the completion of the transaction, the director directly owned 1,765 shares in the company, valued at approximately $30,040.30. This represents a 80.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its position in Sarepta Therapeutics by 454.6% in the 4th quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock valued at $167,781,000 after buying an additional 6,390,860 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Sarepta Therapeutics by 18.1% during the third quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock worth $208,452,000 after acquiring an additional 1,657,267 shares during the last quarter. First Trust Advisors LP lifted its stake in shares of Sarepta Therapeutics by 209.1% in the third quarter. First Trust Advisors LP now owns 1,939,781 shares of the biotechnology company’s stock worth $37,380,000 after acquiring an additional 1,312,220 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Sarepta Therapeutics by 183.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,745,051 shares of the biotechnology company’s stock valued at $33,627,000 after purchasing an additional 1,129,610 shares during the last quarter. Finally, Erste Asset Management GmbH boosted its holdings in Sarepta Therapeutics by 65.7% in the third quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock valued at $50,588,000 after purchasing an additional 1,064,530 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $21.68 on Friday. The firm has a fifty day moving average of $18.71 and a 200-day moving average of $19.97. Sarepta Therapeutics has a 52-week low of $10.41 and a 52-week high of $73.95. The company has a quick ratio of 1.48, a current ratio of 2.32 and a debt-to-equity ratio of 0.73. The firm has a market capitalization of $2.28 billion, a P/E ratio of -2.57, a PEG ratio of 0.37 and a beta of 0.42.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($2.71). Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The business had revenue of $442.93 million for the quarter, compared to analyst estimates of $390.95 million. During the same quarter in the previous year, the firm posted $1.90 EPS. The business’s revenue was down 32.7% compared to the same quarter last year. As a group, analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.